Figure 4.

Therapeutic effect of pIL-13R against subcutaneous murine melanoma. (A) Tumor development in animals vaccinated with pIL-13R. (B) Combined treatment with pIL-13R and drug 7A. (C) Increased survival of pIL-13R and pIL-13R plus drug 7A-treated mice. C57Bl/6 mice were injected with 5 x 10⁴ B16F10-Nex2 tumor cells, and on days 5, 10, 15, 20, 25 and 30, the animals were vaccinated with pIL-13R (plasmid VR1012 containing the insert IL-13Rα2-Fc; (A). The same protocol was used in association with drug 7A (B). Drug 7A was administered i.p. three times a week, 10 µM per animal. Control groups were vaccinated with empty plasmid. For each group, n = 10. Kaplan-Meier test for the control and the vaccinated groups with pIL-13R (P = .0298) or with pIL-13R + drug 7A (P = .0005).